Lidds AB (FRA:5LD) 3-Year EBITDA Growth Rate: 70.70% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lidds AB 3-Year EBITDA Growth Rate?

Lidds AB FRA:5LD 3-Year EBITDA Growth Rate is 70.70% as of Sep. 2025. The stock has 2 warning signs investors should review.

Lidds AB's EBITDA per Share for the three months ended in Sep. 2025 was €-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 70.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 47.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 8.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Lidds AB was 70.70% per year. The lowest was -52.70% per year. And the median was -9.70% per year.

Lidds AB  (FRA:5LD) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Lidds AB 3-Year EBITDA Growth Rate Related Terms

FRA:5LD vs VRTX, REGN, ALNY: 3-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Lidds AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lidds AB 3-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lidds AB's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Lidds AB's 3-Year EBITDA Growth Rate falls into.


Lidds AB 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 70.70% mean?
Lidds AB (FRA:5LD) has a 3-Year EBITDA Growth Rate of 70.70% as of Sep. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lidds AB and its competitors.
Is Lidds AB's 3-Year EBITDA Growth Rate too high?
Lidds AB's current 3-Year EBITDA Growth Rate is 70.70%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Lidds AB's value of 70.70% is 376.1% above this industry median.
How does Lidds AB's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
Lidds AB's 3-Year EBITDA Growth Rate of 70.70% can be compared against companies in the Biotechnology industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Lidds AB's value of 70.70% is 376.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lidds AB's current 3-Year EBITDA Growth Rate of 70.70% is 376.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lidds AB and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lidds AB's current 3-Year EBITDA Growth Rate is 70.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lidds AB stock overvalued right now?
Lidds AB (FRA:5LD) has a current 3-Year EBITDA Growth Rate of 70.70%. The current 3-Year EBITDA Growth Rate is 70.70% and 376.1% above the Biotechnology industry median of 14.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Lidds AB (FRA:5LD), the current 3-Year EBITDA Growth Rate is 70.70% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lidds AB Business Description

Address c/o Excore, Kungsportsavenyen 22, Goteborg, SWE, 411 36
Lidds AB is a Sweden-based drug delivery company focused on its proprietary NanoZolid technology platform. The NanoZolid system is used to formulate drugs for local administration with controlled and sustained release over extended periods. The company offers this technology to partners and is also developing its own pipeline of drug candidates, prominently in oncology, where the platform is used to enable localized and sustained drug delivery. It has a pipeline with several projects in clinical development, both in early- and late-stage clinical phases, and projects about to enter clinical development.